DPP4 and type 2 diabetes mellitus: Dipeptidyl peptidase-4 (DPP-4) inhibitors including the DPP-4 inhibitor class of glyptins (e.g., sitagliptin, vildagliptin, linagliptin), are treatments approved for the treatment of type 2 diabetes.